Clinical trials: Autonomic Dysfunction
Multiple System Atrophy
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the…
- Trial name
- NCT07729852
- Testing
- ATH434
- Where
- 4 sites in France
- Volunteers
- 7 people
- Sponsor
- Alterity Therapeutics
Orthostatic Hypotension
Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients
Orthostatic hypotension is a major complication of hemodialysis and interferes with everyday activities in hemodialysis patients.
- Trial name
- OH (NCT01612078)
- Testing
- Droxidopa
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- TSH Biopharm Corporation Limited
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH302 (NCT00633880)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 181 people
- Sponsor
- Chelsea Therapeutics
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Complex Regional Pain Syndrome (RSD)
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally.
- Trial name
- CRPS (NCT00067743)
- Testing
- Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Parkinson Disease, Progressive Supranuclear Palsy(PSP)
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
This is an observational longitudinal study in 4 cohorts of patients with Parkinsonian syndromes, who are visiting the Movement Disorders outpatient clinics.
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy
- Trial name
- PARATROOPER (NCT06597071)
- Testing
- NeuraLight PD, NeuraLight PSP, NeuraLight MSA
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Orthostatic Hypotension, Parkinson's Disease
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease.
- Trial name
- 306A/306B (NCT01176240)
- Testing
- Droxidopa
- Where
- 60 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chelsea Therapeutics
Multiple System Atrophy
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
- Trial name
- NCT00977665
- Testing
- rasagiline mesylate
- Where
- 47 sites in United States, Austria and 10 more
- Volunteers
- 174 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cardiac Pacemaker, Arrythmia
Aveir DR Real-World Evidence Post-Approval Study
The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.
- Conditions
- Cardiac Pacemaker, Arrythmia, Bradycardia
- Trial name
- NCT05935007
- Testing
- Aveir DR Leadless Pacemaker System
- Where
- United States
- Volunteers
- 1,805 people
- Sponsor
- Abbott Medical Devices
Complex Regional Pain Syndrome Type I
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
- Trial name
- CRPS-RISE (NCT07210515)
- Testing
- Neridronate
- Where
- 31 sites in United States
- Volunteers
- 270 people
- Sponsor
- Ambros Therapeutics, Inc.
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
This trial will the efficacy of KM-819 compared to placebo in subjects with MSA for slowing the progression of MSA.
- Trial name
- NCT05695378
- Testing
- KM-819
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Kainos Medicine Inc.